Clinical Trials

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT05312372 2026-02-17

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Phase 1/2 Withdrawn

Esophageal Squamous Cell Carcinoma

NCT06644781 2026-01-12

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Phase 3 Recruiting

510 enrolled

Esophageal Squamous Cell Carcinoma

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Phase 1/2 Completed

90 enrolled

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04949256 2025-12-15

MK-7902-014

864 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT01142388 2025-11-25

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

94 enrolled 8 charts

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05189730 2025-11-20

ETNT

80 enrolled

Esophageal Squamous Cell Carcinoma

NCT06143748 2025-09-17

EC-CRT-006

46 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

3 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

NCT03783442 2025-07-29

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Completed

649 enrolled 22 charts

Esophageal Squamous Cell Carcinoma

NCT05357846 2025-06-12

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Phase 3 Recruiting

422 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06637163 2025-04-17

Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC

100 enrolled

Esophageal Squamous Cell Carcinoma

NCT04804696 2025-02-21

Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

Phase 2 Terminated

10 enrolled

Esophageal Squamous Cell Carcinoma

NCT05520619 2024-11-18

EC-CRT-002

114 enrolled

Phase EARLY_PHASE1 Recruiting

Esophageal Squamous Cell Carcinoma

NCT06690476 2024-11-15

Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma

74 enrolled

Esophageal Squamous Cell Carcinoma

NCT03430843 2024-10-26

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Completed

512 enrolled 27 charts

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT05490719 2024-05-21

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

39 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Phase 1/2 Completed

73 enrolled 18 charts

Phase 1/2 Enrolling by invitation

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06303583 2024-03-12

CRIS

30 enrolled

Esophageal Squamous Cell Carcinoma

NCT04568200 2024-01-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Completed

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT02916511 2023-12-22

ESO-Shanghai9

Phase 2 Completed

70 enrolled

Esophageal Squamous Cell Carcinoma

NCT03748134 2023-10-24

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Phase 3 Completed

746 enrolled

Phase NA Enrolling by invitation

Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Neoplasms, Squamous Cell

NCT06048926 2023-09-21

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

30 enrolled

Esophageal Squamous Cell Carcinoma

NCT04764227 2023-08-03

Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)

70 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05281003 2023-07-13

HYPERION

128 enrolled